Wall Street analysts predict that Mediwound Ltd (NASDAQ:MDWD) will announce earnings per share of ($0.16) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Mediwound’s earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.17). Mediwound posted earnings per share of ($0.09) in the same quarter last year, which indicates a negative year over year growth rate of 77.8%. The firm is expected to report its next earnings results on Tuesday, February 20th.
On average, analysts expect that Mediwound will report full year earnings of ($1.06) per share for the current financial year, with EPS estimates ranging from ($1.11) to ($1.01). For the next fiscal year, analysts expect that the firm will post earnings of ($0.69) per share, with EPS estimates ranging from ($1.16) to ($0.44). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Mediwound.
Mediwound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, November 16th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03. Mediwound had a negative net margin of 904.26% and a negative return on equity of 246.58%.
Mediwound (NASDAQ:MDWD) opened at $4.05 on Wednesday. The firm has a market cap of $117.66, a price-to-earnings ratio of -4.13 and a beta of 0.01. Mediwound has a 12-month low of $3.55 and a 12-month high of $8.25.
Hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Mediwound by 23.5% in the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after buying an additional 12,522 shares during the last quarter. Nationwide Fund Advisors acquired a new stake in shares of Mediwound in the third quarter valued at about $1,538,000. Alyeska Investment Group L.P. acquired a new stake in shares of Mediwound in the third quarter valued at about $2,140,000. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Mediwound by 5,084.4% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 754,434 shares of the biopharmaceutical company’s stock valued at $3,357,000 after buying an additional 739,882 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Mediwound by 9.5% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock valued at $11,882,000 after buying an additional 192,860 shares during the last quarter. Institutional investors and hedge funds own 29.46% of the company’s stock.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.